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Abstract
Background: The Global Burden of Diseases Study 2010 reported that hypertension is worldwide the leading risk factor for
cardiovascular disease, causing 9.4 million deaths annually. We examined to what extent self-measurement of home blood
pressure (HBP) refines risk stratification across increasing categories of conventional blood pressure (CBP).
Methods and Findings: This meta-analysis included 5,008 individuals randomly recruited from five populations (56.6%
women; mean age, 57.1 y). All were not treated with antihypertensive drugs. In multivariable analyses, hazard ratios (HRs)
associated with 10-mm Hg increases in systolic HBP were computed across CBP categories, using the following systolic/
diastolic CBP thresholds (in mm Hg): optimal, ,120/,80; normal, 120–129/80–84; high-normal, 130–139/85–89; mild
hypertension, 140–159/90–99; and severe hypertension, $160/$100. Over 8.3 y, 522 participants died, and 414, 225, and
194 had cardiovascular, cardiac, and cerebrovascular events, respectively. In participants with optimal or normal CBP, HRs
for a composite cardiovascular end point associated with a 10-mm Hg higher systolic HBP were 1.28 (1.01–1.62) and 1.22
(1.00–1.49), respectively. At high-normal CBP and in mild hypertension, the HRs were 1.24 (1.03–1.49) and 1.20 (1.06–1.37),
respectively, for all cardiovascular events and 1.33 (1.07–1.65) and 1.30 (1.09–1.56), respectively, for stroke. In severe
hypertension, the HRs were not significant (p$0.20). Among people with optimal, normal, and high-normal CBP, 67 (5.0%),
187 (18.4%), and 315 (30.3%), respectively, had masked hypertension (HBP$130 mm Hg systolic or $85 mm Hg diastolic).
Compared to true optimal CBP, masked hypertension was associated with a 2.3-fold (1.5–3.5) higher cardiovascular risk. A
limitation was few data from low- and middle-income countries.
Conclusions: HBP substantially refines risk stratification at CBP levels assumed to carry no or only mildly increased risk, in
particular in the presence of masked hypertension. Randomized trials could help determine the best use of CBP vs. HBP in
guiding BP management. Our study identified a novel indication for HBP, which, in view of its low cost and the increased
availability of electronic communication, might be globally applicable, even in remote areas or in low-resource settings.
Please see later in the article for the Editors’ Summary.
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Introduction
Current guidelines for the diagnosis and management of
hypertension recommend risk stratification based on convention-
ally measured blood pressure, i.e., blood pressure measured in a
medical environment [1,2]. European guidelines [1] categorize
blood pressure as optimal, normal, high normal, and grades 1 to 3
of hypertension; US guidelines [2] classify blood pressure as
normal, prehypertension, and stages 1 and 2 of hypertension
(Table 1). Blood pressure self-measured at home is a more
accurate prognosticator than conventionally measured blood
pressure, because of the greater number of readings and the
avoidance of the white-coat effect, as well as avoidance of
measurement error through use of automated blood pressure
monitors [3,4]. Affordable and validated automated monitors for
blood pressure self-measurement are readily available.
The Global Burden of Diseases Study 2010 reported that high
blood pressure is the leading risk factor for global disease burden,
and is estimated to cause 9.4 million deaths every year—more
than half of the estimated 17 million deaths a year caused by total
cardiovascular disease [5]. To succeed in reducing the burden of
hypertension [5,6], efforts should be targeted where they are
needed most [7]. In line with this statement [7], we examined to
what extent blood pressure self-monitoring succeeds in refining
risk stratification within established categories of conventional
blood pressure (CBP), in particular at levels assumed to be
associated with no or only mildly increased risk [1,2]. We
addressed the issue in an individual-participant meta-analysis of
5,008 people not being treated for hypertension randomly
recruited from five populations and enrolled in the International
Database of Home Blood Pressure in Relation to Cardiovascular
Outcome (IDHOCO) [8,9].
Methods
Ethics Statement
All studies included in IDHOCO received ethical approval.
They have been described in detail in peer-reviewed publications.
All participants gave informed written consent.
Search Strategy and Study Inclusion Criteria
Figure 1 describes the selection of studies and participants based
on electronic searches of the literature done in February 2012
before publication of the IDHOCO protocol [8] and repeated in
July 2013. We searched the PubMed database, using as initial
search terms (home blood pressure OR self-measured blood
pressure) AND population AND (‘‘1980/01/01’’[Date - Publica-
tion] : ‘‘2012/02/28’’[Date - Publication]), yielding 791 publica-
tions. We then limited the search as follows: NOT review[Pu-
blication Type] AND general population, resulting in 172 hits.
Two authors (K. A. and T. J. N.) independently reviewed titles and
abstracts. Studies were eligible for inclusion if they met the
following criteria: (1) baseline information on conventional and
self-measured blood pressure and cardiovascular risk factors was
available; (2) the study was reported as an original research study
in a peer-reviewed publication; (3) the study was published
between 1 January 1980 and 28 February 2012; (4) the study
involved a general population sample; and (5) the subsequent
follow-up included both fatal and nonfatal outcomes. After
eliminating duplicate population cohorts, the two authors (K. A.
and T. J. N.) excluded 57 articles because no home blood pressure
(HBP) was measured (n= 34), HBP was not self-measured (n= 4),
the study included patients instead of a population sample (n= 7),
or cardiovascular outcome was not collected (n= 12). J. A. S. and
K. A. assessed nine studies in detail [10–18] and further eliminated
three population cohorts, because no outcome data had been
collected [10], only fatal outcomes had been recorded [14], or
individual-participant data were unavailable [12].
Study Population
At the time of writing this report, IDHOCO included six
eligible population cohorts [11,13,15–18] and 8,486 participants
(Table 2). We discarded one cohort because data on cause-specific
mortality were still being collected [18]. Of the remaining 6,753
participants, we excluded 1,745 because they were on antihyper-
tensive drug treatment initiated before enrollment based on CBP
measurement (n= 1,465), because fewer than two measurements of
their CBP or HBP were on record (n= 270), or because
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information on current smoking or cardiovascular disease history
was unavailable (n= 10). Thus, the number of participants
analyzed totaled 5,008. Analyzed participants were 1,605 Finns
representing a nationwide population sample (the Finn-Home
study) [17]; 568 inhabitants of Didima, Greece [15]; 2,010
residents from Ohasama, Japan [11]; 469 inhabitants of the
Tsurugaya district in Sendai, Japan [16]; and 356 participants
living in Montevideo, Uruguay [13].
Data Collection
IDHOCO was constructed and maintained at the Studies
Coordinating Centre in Leuven, Belgium, in accordance with
Belgian legislation on the protection of privacy [8]. Investigators
provided anonymous information on each participant in electronic
format. After integration of the information into the overarching
database, investigators received detailed summary statistics on
their own cohort. This procedure ensured that the common
database incorporated unbiased information without conflicts
between the originally published reports [11,13,15–17] and results
generated for individual studies as part of the current meta-
analysis.
Blood Pressure Measurement
CBP was measured with a standard mercury sphygmomanom-
eter (Mercuro 300 [17] or Baumomanometer [15]), an automatic
auscultatory (Elquest USM-700F [11]), or a validated oscillometric
monitor (Omron Form ABI/PWV [16] or Omron HEM-705CP
[13]), using the appropriate cuff size, with the participant in the
sitting or supine position. The CBP was the average of two
consecutive readings obtained at an examination center. Next, we
classified the CBP according to the generally accepted thresholds
that are available in the European [1] and US [2] guidelines.
Optimal blood pressure was a level below 120 mm Hg systolic and
below 80 mm Hg diastolic. For normal and high-normal blood
pressure and mild hypertension, systolic/diastolic levels encom-
passed 120–129/80–84 mm Hg, 130–139/85–89 mm Hg, and
140–159/90–99 mm Hg, respectively. Severe hypertension was a
level of 160 mm Hg systolic or 100 mm Hg diastolic or higher. An
additional category, prehypertension, combines participants with
normal and high-normal blood pressure (120–139 mm Hg systolic
or 80–89 mm Hg diastolic). When the systolic and diastolic blood
pressures were in different categories, we assigned the participant
to the higher category.
All participants measured their blood pressure at home after 2–
5 min of rest in the sitting position with a validated oscillometric
device (Omron HEM-722C [17], Omron HEM-705CP [15],
Omron HEM-401C [11], Omron HEM-747 [16], or SpaceLabs
90207 [13]) using the appropriate cuff size. Each participant’s
HBP was the average of all available readings. Masked hyperten-
sion was a CBP of less than 140 mm Hg systolic and 90 mm Hg
diastolic in the presence of a HBP of 130 mm Hg systolic or
85 mm Hg diastolic or higher [1,9]. In sensitivity analyses, we also
used 135 mm Hg as the systolic threshold for HBP to define
masked hypertension [1,2].
Other Measurements
Via questionnaires, we obtained information on each partici-
pant’s medical history and smoking habits. Body mass index was
body weight in kilograms divided by height in meters squared.
Biochemical measurements included serum cholesterol and blood
glucose. Information on serum total cholesterol level was not
available for the Didima population and was, as in previous
publications [8,9], extrapolated from data provided by the
ATTICA study investigators by sex and 10-y age strata. The
ATTICA study population was a large population cohort
examined in the same time period and in the same geographical
area as the Didima cohort [19,20]. Diabetes mellitus was defined
as the use of antidiabetic drugs, a fasting blood glucose
concentration of at least 7.0 mmol/l [21], a random blood glucose
concentration of at least 11.1 mmol/l [21], a self-reported
diagnosis, or diabetes documented in practice or hospital records.
Ascertainment of Events
We ascertained vital status and incidence of fatal and nonfatal
diseases from the appropriate sources in each country, as described
in detail in a previous publication [8]. Fatal and nonfatal stroke did
not include transient ischemic attacks. Cardiac events comprised
fatal and nonfatal myocardial infarction, death because of
ischemic heart disease, sudden death, fatal and nonfatal heart
failure, surgical and percutaneous coronary revascularization,
pacemaker implantation, and other cardiac deaths. The composite
cardiovascular end point included cardiovascular mortality,
cerebrovascular, and cardiac end points. In all outcome analyses,
we considered only the first occurrence per participant in each
event category.
Statistical Analysis
For database management and statistical analysis, we used SAS
software, version 9.3 (SAS Institute). We compared means and
proportions using the standard normal z-test for large samples or
ANOVA and the x2 statistic, respectively. Statistical significance
was a level less than 0.05 on two-sided tests. We plotted incidence
rates by the five categories of CBP, while standardizing by the
direct method for sex and age (,40, 40–59, and $60 y).
Table 1. Classification of conventional blood pressure according to European and American guidelines and the current study.
Systolic BP (mm Hg) Diastolic BP (mm Hg) Blood Pressure Categories
European Guideline [1] American Guideline [2] Current Study
,120 ,80 Optimal Normal Optimal
120–129 80–84 Normal Prehypertension Normal
130–139 85–89 High normal Prehypertension High-normal
140–159 90–99 Grade 1 hypertension Stage 1 hypertension Mild hypertension
160–179 100–109 Grade 2 hypertension Stage 2 hypertension Severe hypertension
$180 $110 Grade 3 hypertension Stage 2 hypertension Severe hypertension
BP indicates blood pressure.
doi:10.1371/journal.pmed.1001591.t001
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We used Cox proportional hazards models to compute hazard
ratios (HRs), while adjusting for cohort as a random effect and for
sex, age, body mass index, smoking, total cholesterol, and history
of cardiovascular disease and diabetes mellitus as fixed effects. We
checked the proportional hazards assumption and the functional
forms of the covariables using the Kolmogorov-type supremum
test, as implemented in the PROC PHREG procedure of the
SAS package. In multivariable-adjusted Cox proportional
hazards models, we explored whether, within each category of
CBP, HBP analyzed as continuous variable refined risk
Figure 1. Flow diagram of selected studies and participants. Electronic searches of the literature were performed in February 2012 before
publication of the IDHOCO protocol [8] and were repeated in July 2013.
doi:10.1371/journal.pmed.1001591.g001
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stratification. We derived HRs that expressed the change in risk
associated with increases in the systolic and diastolic HBP of 10
and 5 mm Hg, respectively. In sensitivity analyses, we computed
the differences in the HRs between subgroups by introducing
the appropriate interaction term in the Cox proportional
hazards models. Finally, we computed multivariable-adjusted
HRs comparing the risk of masked hypertension in participants
with optimal, normal, or high-normal CBP with the risk
incurred by participants with optimal CBP without masked
hypertension. We tested heterogeneity in the HRs among the
three subgroups with masked hypertension by testing an ordinal
variable coding for these subgroups among participants with
masked hypertension.
Results
Baseline Characteristics
Of 5,008 participants, 2,834 (56.6%) were female, 2,115
(42.2%) were 60 y or older, 1,148 (22.9%) were current smokers,
317 (6.3%) had diabetes mellitus, and 327 (6.5%) had a history
of cardiovascular disease. Age averaged 57.1 y (standard
deviation [SD], 13.6). Across all participants, CBP averaged
130.9 (SD, 19.7) mm Hg systolic and 77.9 (SD, 11.5) mm Hg
diastolic. The corresponding means for HBP were 123.9 (SD,
17.2) mm Hg and 74.9 (SD, 9.8) mm Hg. The mean self-
measured HBP was therefore 7.0 mm Hg (95% CI, 6.5–7.4; p,
0.0001) and 3.0 mm Hg (95% CI, 2.8–3.3; p,0.0001) lower
than mean CBP. Table 3 lists the baseline characteristics of the
5,008 participants by CBP category. All of the ANOVA and x2
statistic p-values for differences across the five categories were
significant (p#0.015) except for the prevalence of smoking
(p = 0.083).
Incidence of Events
Median follow-up was 8.3 y (5th to 95th percentile interval,
4.7 to 16.8) and ranged by study from 5.5 y (2.3 to 5.6) in
Tsurugaya to 11.9 y (3.8 to 16.9) in Ohasama (Table 2).
During 46,593 person-years of follow-up, 522 participants died
(11.2 per 1,000 person-years), and 414 experienced a fatal or
nonfatal cardiovascular event (9.1 per 1,000 person-years).
Considering cause-specific first cardiovascular events, the
incidence of stroke and cardiac events amounted to 225 (4.9
per 1,000 person-years) and 194 (4.2 per 1,000 person-years),
respectively.
Risk Associated with Increasing Categories of
Conventional Blood Pressure
Figure 2 displays the Kaplan-Meier survival function estimates.
The log-rank test for difference across the categories of CBP was
highly significant for all of the end points under study (p,0.0001).
Similarly, incidence rates standardized by the direct method for
sex and age (,40, 40–59, and $60 y) increased across the
categories of CBP (Figure 3; p#0.0009). The multivariable-
adjusted HRs, expressing the risk compared with optimal blood
pressure (Table 4), increased with higher categories of CBP for
total mortality (p= 0.011) as well as for fatal combined with
nonfatal outcomes (p#0.0004).
Risk Associated with Home Blood Pressure by Category
of Conventional Blood Pressure
Among participants with an optimal CBP, the multivariable-
adjusted HRs associated with a 10-mm Hg increment in home
systolic blood pressure were 1.21 (95% CI, 1.00–1.46) and 1.28
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(95% CI, 1.01–1.62) for total mortality and cardiovascular events.
The corresponding HRs among participants with normal CBP
were 1.18 (95% CI, 0.99–1.40) and 1.22 (95% CI, 1.00–1.49),
respectively. The home systolic blood pressure also predicted the
composite cardiovascular end point and stroke (Table 5) in
participants with high-normal blood pressure, prehypertension,
and mild hypertension. For these categories, the HRs for the
composite cardiovascular end point were 1.24 (95% CI, 1.03–
1.49), 1.24 (95% CI, 1.09–1.41), and 1.20 (95% CI, 1.06–1.37),
respectively, and for stroke were 1.33 (95% CI, 1.07–1.65), 1.27
(95% CI, 1.08–1.50), and 1.30 (95% CI, 1.09–1.56), respective-
ly. However, in participants with severe hypertension, the HBP
did not significantly add to the prediction of any end point
under study (p$0.20). The home diastolic blood pressure was a
weak and inconsistent predictor across the categories of CBP
(Table 6).
Excluding one cohort at a time or stratifying participants by
sex, ethnicity, or age (,60 versus $60 y) confirmed the main
analyses of home systolic blood pressure, as reported in Tables 7
and 8.
Characteristics of Participants with Masked Hypertension
Participants with masked hypertension according to the 130/
85-mm Hg threshold, compared with participants with true
optimal, normal, or high-normal blood pressure (Table 9), were
more likely to be male (51.0% versus 38.7%; p,0.0001), to smoke
(28.1% versus 23.2%; p = 0.012), to have diabetes mellitus (10.5%
versus 4.9%; p,0.0001) or a history of cardiovascular disease
(8.3% versus 5.2%; p = 0.0038), and to be older (62.9 versus
53.2 y; p,0.0001) and more obese (26.0 versus 24.3 kg/m2; p,
0.0001).
Participants with masked hypertension according to the 135/
85-mm Hg threshold, compared with participants with true
optimal, normal, or high-normal blood pressure (Table 10), were
more likely to be male (55.7% versus 38.7%; p,0.0001), to smoke
(29.6% versus 23.3%; p= 0.0053), to have diabetes mellitus (11.6%
versus 5.1%; p,0.0001) or a history of cardiovascular disease
(9.1% versus 5.2%; p= 0.0015), and to be older (62.8 versus
53.7 y; p,0.0001) and more obese (26.5 versus 24.4 kg/m2; p,
0.0001).
Risk Conferred by Masked Hypertension
Using 130/85 mm Hg as threshold for HBP to define masked
hypertension (Figure 4; Table 9), the number of participants with
masked hypertension amounted to 67 (5.0%), 187 (18.4%), and
315 (30.3%) among participants with optimal, normal, and high-
normal blood pressure, respectively. In these three categories of
participants with masked hypertension, with optimal blood
pressure without masked hypertension as reference, the multivar-
iable-adjusted HRs for total mortality were 2.21 (95% CI, 1.27–
3.85), 1.57 (95% CI, 1.02–2.41), and 1.54 (95% CI, 1.07–2.23),
respectively. The corresponding HRs for the composite cardio-
vascular end point were 2.65 (95% CI, 1.30–5.34), 2.25 (95% CI,
1.33–3.80), and 2.24 (95% CI, 1.41–3.53), respectively.
Using 135/85 mm Hg as the HBP threshold to define masked
hypertension (Figure 5; Table 10), the number of participants with
masked hypertension amounted to 42 (3.1%), 131 (12.9%), and
233 (22.4%) among participants with optimal, normal, and high-
normal blood pressure, respectively. In these three categories of
participants with masked hypertension, with optimal blood
pressure without masked hypertension as reference, the multivar-
iable-adjusted HRs for total mortality were 1.91 (95% CI, 0.98–
3.74), 1.66 (95% CI, 1.04–2.63), and 1.47 (95% CI, 0.98–2.22),
respectively. The corresponding HRs for the composite cardio-
vascular end point were 2.14 (95% CI, 0.89–5.15), 1.96 (95% CI,
1.09–3.52), and 1.87 (95% CI, 1.13–3.09), respectively.
Table 3. Participants characteristics according to conventional blood pressure categories.
Characteristic Optimal (n=1,337) Normal (n=1,015)
High-Normal
(n=1,038)
Mild Hypertension
(n=1,126)
Severe Hypertension
(n=492)
Number (percent) with characteristic
Women 900 (67.3) 570 (56.2)` 538 (51.8)* 573 (50.9) 253 (51.4)
Current smoking 333 (24.9) 238 (23.5) 243 (23.4) 236 (21.0) 98 (19.9)
Diabetes mellitus 60 (4.5) 64 (6.3) 74 (7.1) 79 (7.0) 40 (8.1)
Previous cardiovascular diseases 70 (5.2) 55 (5.4) 68 (6.6) 97 (8.6) 37 (7.5)
White (race) 724 (54.2) 457 (45.0)` 488 (47.0) 589 (52.3)* 271 (55.1)
Mean (SD) of characteristic
Age (years) 50.9 (14.1) 56.1 (12.8)` 58.5 (12.5)` 61.0 (12.1)` 64.1 (11.6)`
Body mass index (kg/m2) 23.9 (3.6) 24.7 (3.8)` 25.4 (4.0){ 26.1 (4.3)` 26.6 (4.6)*
Total cholesterol (mmol/l) 5.19 (0.95) 5.38 (1.00)` 5.43 (1.06) 5.62 (1.12)` 5.87 (1.22)`
Conventional systolic pressure (mm Hg) 109.0 (7.6) 123.3 (4.5)` 132.5 (5.5)` 145.6 (7.6)` 168.6 (14.7)`
Conventional diastolic pressure (mm Hg) 67.6 (6.8) 74.3 (6.6)` 78.9 (7.8)` 85.3 (8.3)` 94.8 (10.9)`
Home systolic pressure (mm Hg) 110.3 (10.9) 119.3 (12.1)` 124.4 (12.4)` 133.8 (14.5)` 146.5 (17.7)`
Home diastolic pressure (mm Hg) 68.2 (7.6) 73.1 (8.0)` 75.4 (8.0)` 79.7 (8.7)` 84.8 (10.1)`
White (race) included Finns, Greeks and Uruguayans. Systolic/diastolic thresholds for CBP were as follows: optimal, ,120/,80 mm Hg; normal, 120–129/80–84 mm Hg;
high-normal, 130–139/85–89 mm Hg; mild hypertension, 140–159/90–99 mm Hg; and severe hypertension, $160/$100 mm Hg. When the systolic and diastolic blood
pressures were in different categories, the participant was assigned to the higher category. All of the ANOVA and x2 statistic p-values for differences across the five
categories were significant (p#0.015) except for the prevalence of smoking (p= 0.083). Significance of the difference with the adjacent lower category of CBP: *p,0.05;
{p,0.001; and `p,0.0001.
doi:10.1371/journal.pmed.1001591.t003
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Discussion
Current guidelines for the diagnosis and management of
hypertension [1,2] stratify risk and treatment decisions based on
defined categories of CBP (Table 1), as measured in a medical
environment. Self-measured HBP or ambulatory blood pressure is
a more accurate prognosticator than CBP. Expert committees
therefore recommend the use of out-of-the-office blood pressure
measurement to confirm the diagnosis of hypertension and assess
treatment effects [1,2]. The key finding of our current study is that
HBP substantially refines risk stratification at levels of CBP that
are presumably associated with no or only mildly elevated risk. In
Figure 2. Kaplan-Meier survival function estimates by five categories of conventional blood pressure in 5,008 participants. (A)
indicates risk for total mortality, and (B–D) indicate risks for cardiovascular events, stroke, and cardiac events, respectively. CBP categories were
optimal (,120/,80 mm Hg), normal (120–129/80–84 mm Hg), high-normal (130–139/85–89 mm Hg), mild hypertension (140–159/90–99 mm Hg),
and severe hypertension ($160/$100 mm Hg). When the systolic and diastolic blood pressures were in different categories, the participant was
assigned to the higher category. The significance of the log-rank test for difference across the five categories was significant (p,0.0001) for all of the
end points.
doi:10.1371/journal.pmed.1001591.g002
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contrast, in severe hypertension, self-measured HBP did not
improve the prediction of death or cardiovascular complications.
To the best of our knowledge, only one previous prospective
study addressed risk stratification by out-of-the-office blood
pressure measurement in prehypertensive patients, but applied
ambulatory monitoring instead of self-measurement. Pierdome-
nico and coworkers [22] followed the incidence of cardiovascular
events in prehypertensive participants with (n= 120) or without
(n= 471) masked hypertension. The participants were hospital
staff, patients referred for reasons other than cardiovascular
disease or hypertension, and volunteers. During 6.6 y of follow-up,
29 fatal and nonfatal cardiovascular events occurred. In pre-
hypertensive patients without and with masked hypertension, the
event rates per 100 patient-years were 0.57 and 1.51, respectively.
With adjustments applied for covariables, including CBP, cardio-
vascular risk was significantly higher in masked hypertensive
patients than in true prehypertension (masked versus true
prehypertension without elevated ambulatory blood pressure,
relative risk 2.65; 95% CI, 1.18–5.98; p= 0.018).
According to the European Society of Hypertension guidelines
[1], masked hypertension is a clinic blood pressure below
140 mm Hg systolic and 90 mm Hg diastolic in the presence of
a daytime or self-measured blood pressure of at least 130 mm Hg
or 135 mm Hg systolic or 85 mm Hg diastolic. The prevalence of
masked hypertension in our current study was 8.4%, which is of
the same order of magnitude as in other individual-participant
meta-analyses of population samples [23,24]. If one accounts for
differences in the technique of out-of-the-office blood pressure
measurement, treatment status, and applied thresholds, masked
hypertension carries a risk that approaches that of sustained
hypertension [23,24]. In keeping with our current findings
(Tables 9 and 10), the Finn-Home study investigators demonstrat-
ed that high-normal systolic and diastolic office blood pressure,
older age, greater body mass index, current smoking, and diabetes
were independent determinants of masked hypertension [25].
Similarly, Franklin and coworkers [24] reported that among
people not being treated for hypertension, the prevalence of
masked hypertension, using a daytime ambulatory threshold of
135/85 mm Hg, was higher in diabetic than nondiabetic partic-
ipants (18.1% versus 13.8%; p= 0.032).
Figure 3. Incidence rates in 5,008 participants by increasing
categories of conventional blood pressure. Rates (given as end
points per 1,000 person-years) were standardized for sex and age by the
direct method. CBP categories were optimal (,120/,80 mm Hg),
normal (120–129/80–84 mm Hg), high-normal (130–139/85–
89 mm Hg), mild hypertension (140–159/90–99 mm Hg), and severe
hypertension ($160/$100 mm Hg). When the systolic and diastolic
blood pressures were in different categories, the participant was
assigned to the higher category. The number of end points
contributing to the rates is presented. The p-values refer to the
significance for linear trend across the five categories of CBP. HT,
hypertension.
doi:10.1371/journal.pmed.1001591.g003
Table 4. Risks associated with increasing categories of conventional blood pressure.
End Point Statistic CBP Category p-Value
Optimal Normal High-Normal Mild Hypertension Severe Hypertension
Total mortality Number (percent) 90 (6.7) 101 (10.0) 124 (12.0) 127 (11.3) 80 (16.3)
HR (95% CI) 1.00 1.15 (0.86–1.53) 1.16 (0.88–1.53) 1.13 (0.86–1.49) 1.71 (1.25–2.33)` 0.011
Cardiovascular events Number (percent) 53 (4.0) 70 (6.9) 85 (8.2) 124 (11.0) 82 (16.7)
HR (95% CI) 1.00 1.33 (0.93–1.90) 1.33 (0.94–1.89) 1.76 (1.26–2.45){ 2.59 (1.81–3.73)` ,0.0001
Stroke Number (percent) 26 (1.9) 40 (3.9) 57 (5.5) 68 (6.0) 34 (6.9)
HR (95% CI) 1.00 1.56 (0.95–2.57) 1.89 (1.18–3.02)* 2.24 (1.41–3.56){ 2.72 (1.60–4.62){ ,0.0001
Cardiac events Number (percent) 27 (2.0) 31 (3.1) 29 (2.8) 59 (5.2) 48 (9.8)
HR (95% CI) 1.00 1.16 (0.69–1.96) 0.86 (0.51–1.47) 1.42 (0.88–2.28) 2.40 (1.46–3.96){ 0.0004
Number and HR indicate the number of end points (percentage rate) and HR (95% confidence interval), respectively. Systolic/diastolic thresholds for CBP were as
follows: optimal, ,120/,80 mm Hg; normal, 120–129/80–84 mm Hg; high-normal, 130–139/85–89 mm Hg; mild hypertension, 140–159/90–99 mm Hg; and severe
hypertension, $160/$100 mm Hg. When the systolic and diastolic blood pressures were in different categories, the participant was assigned to the higher category.
HRs express the risk compared with optimal blood pressure (reference). HRs were adjusted for cohort as a random effect and for sex, age, body mass index, smoking,
total cholesterol, diabetes mellitus, and history of cardiovascular disease as fixed effects. The p-value refers to linear trend across the blood pressure categories.
Significance of the HRs: *p,0.01; {p,0.001; and `p,0.0001.
doi:10.1371/journal.pmed.1001591.t004
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Our current findings have important implications for clinical
practice. The relation between cardiovascular complications and
blood pressure is continuous at least down to a CBP level of
115 mm Hg systolic or 75 mm Hg diastolic [26]. The continuous
nature of the relation with blood pressure holds true not only in
hypertensive patients, but in normotensive people as well, so that,
for instance, of all strokes, three-fourths occur in individuals with
normal CBP and only one-fourth in patients with hypertension as
determined by CBP [26]. In our current analysis, we demonstrated
that HBP monitoring substantially refines risk stratification in
normotensive people not being treated for hypertension with
optimal, normal, or high-normal CBP, in particular in the presence
of masked hypertension. Consequently, we suggest that in
individuals at risk for masked hypertension, HBP monitoring
should be included in the strategy of primary prevention of
cardiovascular complications. Risk factors that identify people who
would qualify for HBP monitoring are above optimal levels of CBP,
older age, obesity, smoking, and diabetes mellitus [24,25]. HBP
monitoring should also be carried out in people with a normal CBP
but with unexplained signs of hypertensive target organ damage.
Using HBP measurement to screen for masked hypertension is
probably cost-effective. Fukunaga and coworkers studied the cost-
effectiveness of HBP measurement from the perspective of the
Japanese health care system, using simulations based on the
Ohasama population study [27]. Depending on the model applied,
estimates of the cost savings produced by applying HBP
measurement ranged from US$674,000 to US$2.51 million
per 5,000 person-years. Two trials of adjusting treatment based
on out-of-the-office blood pressure measurement [28,29] also
reported cost savings compared to conventional sphygmomanom-
etry, by using either ambulatory monitoring [28] or self-
measurement [29] of blood pressure.
Our individual-participant meta-analysis is clearly an advance
over previous publications in the research field of risk stratification
based on blood pressure. To our knowledge, our study is the first
to assess the risk associated with self-measured HBP across
increasing categories of CBP. It raises the issue that the economic
analysis of HBP monitoring should be based on cost-savings not
only via the avoidance of unnecessary treatment [27–29], but
foremost via the addition of quality and years to life in those at
Table 5. Standardized hazard ratios associated with systolic home blood pressure by category of conventional blood pressure.
Category of CBP HR (95% CI)
Total Mortality Cardiovascular Events Stroke Cardiac Events
Optimal 1.21 (1.00–1.46)* 1.28 (1.01–1.62)* 1.26 (0.88–1.79) 1.25 (0.90–1.72)
Normal 1.18 (0.99–1.40) 1.22 (1.00–1.49)* 1.16 (0.89–1.53) 1.29 (0.95–1.75)
High-normal 1.01 (0.86–1.18) 1.24 (1.03–1.49)* 1.33 (1.07–1.65){ 1.03 (0.74–1.43)
Prehypertension 1.08 (0.96–1.21) 1.24 (1.09–1.41){ 1.27 (1.08–1.50){ 1.15 (0.93–1.44)
Mild hypertension 1.04 (0.92–1.18) 1.20 (1.06–1.37){ 1.30 (1.09–1.56){ 1.13 (0.94–1.36)
Severe hypertension 0.95 (0.83–1.09) 0.95 (0.83–1.08) 1.00 (0.82–1.23) 0.89 (0.74–1.06)
Hypertension 1.04 (0.96–1.14) 1.12 (1.02–1.22)* 1.19 (1.05–1.35){ 1.05 (0.93–1.20)
Systolic/diastolic thresholds for CBP were as follows: optimal, ,120/,80 mm Hg; normal, 120–129/80–84 mm Hg; high-normal, 130–139/85–89 mm Hg; mild
hypertension, 140–159/90–99 mm Hg; and severe hypertension, $160/$100 mm Hg. When the systolic and diastolic blood pressures were in different categories, the
participant was assigned to the higher category. The category prehypertension includes participants with normal and high-normal blood pressure, and the category
hypertension includes participants with mild and severe hypertension. The number of people at risk and the number of events are given in Tables 3 and 4, respectively.
HRs reflect the risk associated with a 10-mm Hg increase in home systolic pressure. HRs were adjusted for cohort as a random effect and for sex, age, body mass index,
smoking, total cholesterol, diabetes mellitus, and history of cardiovascular disease as fixed effects. Significance of the HRs: *p,0.05 and {p,0.01.
doi:10.1371/journal.pmed.1001591.t005
Table 6. Standardized hazard ratios associated with diastolic home blood pressure by category of conventional blood pressure.
Category of CBP HR (95% CI)
Total Mortality Cardiovascular Events Stroke Cardiac Events
Optimal 1.04 (0.91–1.19) 1.07 (0.89–1.29) 0.95 (0.72–1.24) 1.19 (0.92–1.55)
Normal 1.01 (0.89–1.14) 1.03 (0.88–1.20) 1.02 (0.83–1.26) 1.05 (0.82–1.35)
High-normal 0.95 (0.84–1.06) 1.09 (0.95–1.26) 1.11 (0.94–1.31) 1.00 (0.77–1.31)
Prehypertension 0.98 (0.90–1.07) 1.07 (0.97–1.19) 1.08 (0.95–1.23) 1.03 (0.86–1.24)
Mild hypertension 1.02 (0.92–1.13) 1.21 (1.09–1.34)` 1.26 (1.10–1.44)` 1.13 (0.96–1.33)
Severe hypertension 0.90 (0.80–1.02) 0.91 (0.81–1.04) 1.04 (0.87–1.25) 0.81 (0.68–0.96)*
Hypertension 1.01 (0.93–1.08) 1.11 (1.03–1.20){ 1.20 (1.08–1.34)` 1.00 (0.89–1.19)
Systolic/diastolic thresholds for CBP were as follows: optimal, ,120/,80 mm Hg; normal, 120–129/80–84 mm Hg; high-normal, 130–139/85–89 mm Hg; mild
hypertension, 140–159/90–99 mm Hg; and severe hypertension, $160/$100 mm Hg. When the systolic and diastolic blood pressures were in different categories, the
participant was assigned to the higher category. The category prehypertension includes participants with normal and high-normal blood pressure, and the category
hypertension includes participants with mild and severe hypertension. The number of people at risk and the number of events are given in Tables 3 and 4, respectively.
HRs reflect the risk associated with a 5-mm Hg increase in home diastolic pressure. HRs were adjusted for cohort as a random effect and for sex, age, body mass index,
smoking, total cholesterol, diabetes mellitus, and history of cardiovascular disease as fixed effects. Significance of the HRs: *p,0.05; {p,0.01; and `p,0.001.
doi:10.1371/journal.pmed.1001591.t006
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Table 8. Sensitivity analysis for total mortality and cardiovascular events according to anthropometric characteristics and
cardiovascular risk factors.
End Point Subgroup Statistic CBP
Optimal Normal High-Normal
Mild
Hypertension
Severe
Hypertension
Total mortality Women E/R 37/900 40/570 54/538 43/573 30/253
HR (95% CI) 1.19 (0.88–1.62) 1.24 (0.95–1.61) 0.96 (0.74–1.25) 1.04 (0.83–1.31) 1.00 (0.79–1.27)
Men E/R 53/437 61/445 70/500 84/553 50/239
HR (95% CI) 1.24 (0.97–1.58) 1.15 (0.91–1.45) 1.06 (0.86–1.30) 0.99 (0.84–1.16) 0.97 (0.82–1.16)
,60 y E/R 28/985 26/636 30/559 25/538 10/175
HR (95% CI) 1.27 (0.85–1.88) 1.52 (1.06–2.20)* 1.26 (0.91–1.77) 1.06 (0.74–1.50) 2.02 (1.20–3.40){
$60 y E/R 62/352 75/379 94/479 102/588 70/317
HR (95% CI) 1.20 (0.96–1.50) 1.14 (0.94–1.39) 0.95 (0.79–1.14) 1.05 (0.92–1.20) 0.90 (0.78–1.04)
Japanese E/R 67/613 78/558 98/550 86/537 54/221
HR (95% CI) 1.20 (0.96–1.51) 1.16 (0.96–1.40) 0.99 (0.83–1.19) 1.11 (0.96–1.28) 0.82 (0.68–0.97)*
1
White (race) E/R 23/724 23/457 26/488 41/589 26/271
HR (95% CI) 1.27 (0.86–1.88) 1.38 (0.93–2.04) 1.06 (0.74–1.50) 0.92 (0.72–1.17) 1.17 (0.91–1.49)
Nonsmokers E/R 56/1,004 69/777 85/795 93/890 63/394
HR (95% CI) 1.18 (0.94–1.49) 1.23 (1.00–1.51)* 0.90 (0.74–1.11) 0.92 (0.79–1.08) 0.91 (0.78–1.05)
Smokers E/R 34/333 32/238 39/243 34/236 17/98
HR (95% CI) 1.28 (0.93–1.77) 1.14 (0.83–1.58) 1.33 (1.01–1.74)* 1.23 (0.99–1.53) 1.27 (0.89–1.81)
Body mass index
,25 kg/m2
E/R 70/921 75/592 88/546 84/525 55/206
HR (95% CI) 1.26 (1.01–1.58)* 1.16 (0.96–1.40) 0.98 (0.81–1.19) 1.08 (0.94–1.25) 0.92 (0.78–1.09)
Body mass index
$25 kg/m2
E/R 20/416 26/423 36/492 43/601 25/286
HR (95% CI) 1.13 (0.75–1.71) 1.23 (0.81–1.87) 1.12 (0.82–1.54) 0.98 (0.77–1.24) 0.87 (0.67–1.14)
Serum cholesterol
,5.69 mmol/l
E/R 77/1,006 80/684 102/675 99/658 59/240
HR (95% CI) 1.22 (0.99–1.50) 1.24 (1.02–1.49)* 0.99 (0.83–1.19) 1.01 (0.88–1.16) 0.89 (0.76–1.04)
Serum cholesterol
$5.69 mmol/l
E/R 13/331 21/331 22/363 28/468 21/252
HR (95% CI) 1.07 (0.64–1.81) 0.80 (0.49–1.29) 1.07 (0.77–1.50) 1.10 (0.84–1.44) 1.24 (0.94–1.63)
Cardiovascular
events
Women E/R 26/900 26/570 37/538 40/573 28/253
HR (95% CI) 1.32 (0.96–1.82) 1.30 (0.96–1.77) 1.16 (0.85–1.56) 1.34 (1.06–1.68)* 0.93 (0.74–1.16)
Men E/R 27/437 44/445 48/500 84/553 54/239
HR (95% CI) 1.26 (0.88–1.80) 1.17 (0.90–1.53) 1.33 (1.06–1.68)* 1.15 (0.97–1.35) 0.99 (0.84–1.18)
,60 y E/R 19/985 26/636 24/559 32/538 20/175
HR (95% CI) 1.71 (1.08–2.71)* 1.44 (0.98–2.11) 1.35 (0.94–1.94) 1.15 (0.85–1.57) 1.18 (0.88–1.59)
$60 y E/R 34/352 44/379 61/479 92/588 62/317
HR (95% CI) 1.18 (0.87–1.61) 1.24 (0.97–1.58) 1.21 (0.98–1.50) 1.21 (1.05–1.39){ 0.91 (0.78–1.05)
Japanese E/R 31/613 44/558 57/550 69/537 39/221
HR (95% CI) 1.43 (1.03–1.99)* 1.39 (1.09–1.76){ 1.37 (1.10–1.70){ 1.33 (1.12–1.58){ 0.81 (0.66–0.99)*
1
White (race) E/R 22/724 26/457 28/488 55/589 43/271
HR (95% CI) 1.17 (0.80–1.71) 0.95 (0.64–1.43) 0.99 (0.69–1.40) 1.06 (0.87–1.29) 1.05 (0.86–1.28)
Nonsmokers E/R 40/1004 51/777 55/795 93/890 62/394
HR (95% CI) 1.44 (1.11–1.88){ 1.13 (0.89–1.44) 1.26 (1.00–1.59)* 1.13 (0.97–1.31) 0.93 (0.80–1.07)
Smokers E/R 13/333 19/238 30/243 31/236 20/98
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high cardiovascular risk even though CBP is normal. Other
strong points are the relatively large sample size representing
populations from Europe, Asia, and South America, and the
removal of participants being treated for hypertension from
the analysis. Our meta-analysis is also an advance over the
contributing individual studies, because none of them had enough
power to address the research question that we set out to answer
or to run sensitivity analyses stratified by anthropometric
characteristics or cardiovascular risk factors. Furthermore,
meta-analyses based on individual participant data, compared
with meta-analyses of summary statistics, have unique advantag-
es, including the possibility of computing survival curves and the
ability to check whether the Cox proportional hazards assump-
tion is fulfilled [30,31]. Finally, we analyzed both fatal and
nonfatal outcomes. The introduction of stroke units to hospitals
and the increasing availability of invasive coronary care and
thrombolysis over the past decades has reduced the case fatality
rate of most cardiovascular complications of hypertension. Not
accounting for nonfatal events therefore seriously limits general-
izability [32].
Table 8. Cont.
End Point Subgroup Statistic CBP
Optimal Normal High-Normal
Mild
Hypertension
Severe
Hypertension
HR (95% CI) 1.02 (0.61–1.69) 1.44 (0.96–2.17) 1.25 (0.91–1.71) 1.38 (1.07–1.79)* 1.03 (0.75–1.40)
Body mass index
,25 kg/m2
E/R 35/921 46/592 54/546 64/525 35/206
HR (95% CI) 1.55 (1.14–2.10){ 1.29 (1.03–1.62)* 1.20 (0.96–1.51) 1.34 (1.13–1.59)` 0.86 (0.70–1.06)
Body mass index
$25 kg/m2
E/R 18/416 24/423 31/492 60/601 47/286
HR (95% CI) 1.02 (0.64–1.61) 0.97 (0.64–1.47) 1.39 (1.01–1.92)* 1.05 (0.85–1.28) 0.94 (0.78–1.14)
Serum cholesterol
,5.69 mmol/l
E/R 40/1,006 48/684 62/675 84/658 48/240
HR (95% CI) 1.46 (1.12–1.91){ 1.37 (1.08–1.74){ 1.43 (1.15–1.78){ 1.19 (1.02–1.40)* 0.95 (0.79–1.13)
Serum cholesterol
$5.69 mmol/l
E/R 13/331 22/331 23/363 40/468 34/252
HR (95% CI) 0.95 (0.52–1.71) 0.95 (0.64–1.42) 0.91 (0.62–1.33) 1.24 (0.98–1.55) 1.00 (0.80–1.23)
E/R indicates the number of end points/participants at risk. White (race) included Finns, Greeks, and Uruguayans. Systolic/diastolic thresholds for CBP were as follows:
optimal, ,120/,80 mm Hg; normal, 120–129/80–84 mm Hg; high-normal, 130–139/85–89 mm Hg; mild hypertension, 140–159/90–99 mm Hg; and severe
hypertension, $160/$100 mm Hg. When the systolic and diastolic blood pressures were in different categories, the participant was assigned to the higher category.
HRs reflect the risk for a 10-mm Hg increase in home systolic pressure and were adjusted for cohort as a random effect and for sex, age, body mass index, smoking, total
cholesterol, diabetes mellitus, and history of cardiovascular disease as fixed effects. Significance of the HRs: *p,0.05; {p,0.01; and `p,0.001.
1indicates a significant difference (p#0.05) in the HRs between corresponding strata.
doi:10.1371/journal.pmed.1001591.t008
Table 9. Characteristics of participants with masked hypertension (home blood pressure $130/$85 mm Hg) compared with
participants with true optimal, normal, or high-normal blood pressure (home blood pressure ,130/,85 mm Hg).
Characteristic HBP ,130/,85 mm Hg HBP $130/$85 mm Hg
Optimal (n=1,270) Normal (n=828)
High-Normal
(n=723) Optimal (n=67) Normal (n=187)
High-Normal
(n=315)
Number (percent) with characteristic
Women 859 (67.6) 479 (57.9)1 391 (54.1) 41 (61.2) 91 (48.7) 147 (46.7)
Current smoking 316 (24.9) 189 (22.8) 149 (20.6) 17 (25.4) 49 (26.2) 94 (29.8)
Diabetes mellitus 53 (4.2) 45 (5.4) 40 (5.5) 7 (10.5) 19 (10.2) 34 (10.8)
Previous cardiovascular diseases 62 (4.9) 37 (4.5) 47 (6.5) 8 (12.0) 18 (9.6) 21 (6.7)
Mean characteristic (SD)
Age (years) 50.4 (13.9) 54.5 (12.5)1 56.5 (12.5){ 61.3 (13.5) 63.2 (11.7) 63.0 (11.4)
Body mass index (kg/m2) 23.9 (3.6) 24.5 (3.6)` 25.0 (3.7)* 24.8 (4.1) 25.8 (4.3) 26.3 (4.5)
Total cholesterol (mmol/l) 5.20 (0.94) 5.38 (1.01)1 5.40 (1.04) 5.11 (1.08) 5.34 (0.97) 5.50 (1.09)
Systolic/diastolic thresholds for CBP were as follows: optimal, ,120/,80 mm Hg; normal, 120–129/80–84 mm Hg; and high-normal, 130–139/85–89 mm Hg. When the
systolic and diastolic blood pressures were in different categories, the participant was assigned to the higher category. Significance of the difference from the adjacent
lower category of CBP: *p,0.05; {p,0.01; `p,0.001; and 1p,0.0001.
doi:10.1371/journal.pmed.1001591.t009
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On the other hand, our study also has some potential
limitations. First, we did not determine the reproducibility of
masked hypertension in the context of our current study.
However, Viera and colleagues reported prevalence rates of
masked hypertension among patients not being treated with
hypertension but with borderline elevated CBP to be 54% and
53% on first and repeat assessment, with an agreement of 73%
[33]. Among patients who underwent repeated ambulatory
monitoring for a medical indication, Ben-Dov and coworkers
reported an agreement of 72% in the classification of masked
hypertension [34]. Second, CBP values in our study were the
average of only two readings obtained at a single exami-
nation, which can lead to an overestimation of CBP because of
the white-coat effect. However, overestimation of CBP would
weaken rather than strengthen our current findings. Moreover,
our findings were consistent using a tight (130 mm Hg) and less
stringent (135 mm Hg) systolic threshold to define masked
hypertension. Third, IDHOCO has no information on treatment
status during follow-up. However, antihypertensive treatment
instituted during follow-up likely would have been instituted
according to current guidelines and based on CBP. Even if
treatment had been started during follow-up based on HBP, if
anything this would have weakened associations between
outcomes and HBP (including masked hypertension). Fourth,
few data were available from low- and middle-income countries.
Finally, methods of blood pressure measurement and ascertain-
Table 10. Characteristics of participants with masked hypertension (home blood pressure $135/$85 mm Hg) compared with
participants with true optimal, normal, or high-normal blood pressure (home blood pressure ,135/,85 mm Hg).
Characteristic HBP ,135/,85 mm Hg HBP $135/$85 mm Hg
Optimal (n=1,295) Normal (n=884)
High-Normal
(n=805) Optimal (n=42) Normal (n=131)
High-Normal
(n=233)
Number (percent) with characteristic
Women 874 (67.5) 513 (58.0)` 441 (54.8) 26 (61.9) 57 (43.5)* 97 (41.6)
Current smoking 321 (24.8) 202 (22.9) 171 (21.2) 12 (28.6) 36 (27.5) 72 (30.9)
Diabetes mellitus 55 (4.3) 50 (5.7) 46 (5.7) 5 (11.9) 14 (10.7) 28 (12.0)
Previous cardiovascular diseases 66 (5.1) 39 (4.4) 51 (6.3) 4 (9.5) 16 (12.2) 17 (7.3)
Mean characteristic (SD)
Age (years) 50.6 (14.0) 55.1 (12.7)` 57.3 (12.5){ 62.0 (11.2) 63.3 (11.7) 62.6 (11.6)
Body mass index (kg/m2) 23.9 (3.6) 24.5 (3.6){ 25.0 (3.7)* 25.4 (4.2) 26.2 (4.6) 26.8 (4.8)
Total cholesterol (mmol/l) 5.20 (0.94) 5.39 (1.00)` 5.39 (1.05) 5.06 (1.15) 5.29 (0.98) 5.56 (1.08)*
Systolic/diastolic thresholds for CBP were as follows: optimal, ,120/,80 mm Hg; normal, 120–129/80–84 mm Hg; and high-normal, 130–139/85–89 mm Hg. When the
systolic and diastolic blood pressures were in different categories, the participant was assigned to the higher category. Significance of the difference from the adjacent
lower category of CBP: *p,0.05; {p,0.001; and `p,0.0001.
doi:10.1371/journal.pmed.1001591.t010
Figure 4. Hazard ratios associated with masked hypertension ($130/$85 mm Hg) in participants with optimal, normal, and high-
normal conventional blood pressure. Participants with optimal blood pressure without elevated HBP were the reference group. The categories
of CBP were optimal (,120/,80 mm Hg), normal (120–129/80–84 mm Hg), and high-normal (130–139/85–89 mm Hg). When the systolic and
diastolic blood pressures were in different categories, the participant was assigned to the higher category. Systolic/diastolic thresholds for
hypertension on home measurement were$130/$85 mm Hg. The HRs were adjusted for cohort as random effect and for sex, age, body mass index,
smoking, total cholesterol, diabetes mellitus, and history of cardiovascular disease as fixed effects. Horizontal lines denote the 95% confidence
interval. The diamond represents the pooled estimate in all participants with masked hypertension (MHT). The p-value for heterogeneity was derived
by testing an ordinal variable in Cox proportional hazards regression coding for the three subgroups among participants with masked hypertension.
doi:10.1371/journal.pmed.1001591.g004
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ment of events were not identical among cohorts. However, we
accounted for cohort as a random effect in the Cox proportional
hazards models, and our findings remained consistent when we
excluded one cohort at a time.
In conclusion, HBP monitoring substantially refines risk stratifi-
cation in people with levels of CBP assumed to carry no or only
mildly elevated risk, in particular in the presence of masked
hypertension. Properly designed randomized clinical trials are
required to determine whether identification and treatment of
masked hypertension versus the current standard of care, i.e., not to
perform HBP measurement and not to treat people with normal
blood pressure on conventional measurement, leads to a reduction of
cardiovascular complications and is cost-effective. Such trials might
be mounted worldwide in developed and developing countries,
including remote areas and even in low-resource settings [35].
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Editors’ Summary
Background. Globally, hypertension (high blood pressure) is
the leading risk factor for cardiovascular disease and is
responsible for 9.4 million deaths annually from heart attacks,
stroke, and other cardiovascular diseases. Hypertension,
which rarely has any symptoms, is diagnosed by measuring
blood pressure, the force that blood circulating in the body
exerts on the inside of large blood vessels. Blood pressure is
highest when the heart is pumping out blood (systolic blood
pressure) and lowest when the heart is refilling (diastolic
blood pressure). European guidelines define optimal blood
pressure as a systolic blood pressure of less than 120
millimeters of mercury (mm Hg) and a diastolic blood
pressure of less than 80 mm Hg (a blood pressure of less
than 120/80 mm Hg). Normal blood pressure, high-normal
blood pressure, and mild hypertension are defined as blood
pressures in the ranges 120–129/80–84 mm Hg, 130–139/85–
89 mm Hg, and 140–159/90–99 mm Hg, respectively. A
blood pressure of more than 160 mm Hg systolic or
100 mm Hg diastolic indicates severe hypertension. Many
factors affect blood pressure; overweight people and individ-
uals who eat salty or fatty food are at high risk of developing
hypertension. Lifestyle changes and/or antihypertensive
drugs can be used to control hypertension.
WhyWas This Study Done? The current guidelines for the
diagnosis and management of hypertension recommend risk
stratification based on conventionally measured blood
pressure (CBP, the average of two consecutive measure-
ments made at a clinic). However, self-measured home blood
pressure (HBP) more accurately predicts outcomes because
multiple HBP readings are taken and because HBP measure-
ment avoids the ‘‘white-coat effect’’—some individuals have
a raised blood pressure in a clinical setting but not at home.
Could risk stratification across increasing categories of CBP
be refined through the use of self-measured HBP, particularly
at CBP levels assumed to be associated with no or only
mildly increased risk? Here, the researchers undertake a
participant-level meta-analysis (a study that uses statistical
approaches to pool results from individual participants in
several independent studies) to answer this question.
What Did the Researchers Do and Find? The researchers
included 5,008 individuals recruited from five populations
and enrolled in the International Database of Home Blood
Pressure in Relation to Cardiovascular Outcome (IDHOCO) in
their meta-analysis. CBP readings were available for all the
participants, who measured their HBP using an oscillometric
device (an electronic device for measuring blood pressure).
The researchers used information on fatal and nonfatal
cardiovascular, cardiac, and cerebrovascular (stroke) events
to calculate the hazard ratios (HRs, indicators of increased
risk) associated with a 10-mm Hg increase in systolic HBP
across standard CBP categories. In participants with optimal
CBP, an increase in systolic HBP of 10-mm Hg increased the
risk of any cardiovascular event by nearly 30% (an HR of
1.28). Similar HRs were associated with a 10-mm Hg increase
in systolic HBP for all cardiovascular events among people
with normal and high-normal CBP and with mild hyperten-
sion, but for people with severe hypertension, systolic HBP
did not significantly add to the prediction of any end point.
Among people with optimal, normal, and high-normal CBP,
5%, 18.4%, and 30.4%, respectively, had a HBP of 130/85 or
higher (‘‘masked hypertension,’’ a higher blood pressure in
daily life than in a clinical setting). Finally, compared to
individuals with optimal CBP without masked hypertension,
individuals with masked hypertension had more than double
the risk of cardiovascular disease.
What Do These Findings Mean? These findings indicate
that HBP measurements, particularly in individuals with
masked hypertension, refine risk stratification at CBP levels
assumed to be associated with no or mildly elevated risk of
cardiovascular disease. That is, HBP measurements can
improve the prediction of cardiovascular complications or
death among individuals with optimal, normal, and high-
normal CBP but not among individuals with severe hyper-
tension. Clinical trials are needed to test whether the
identification and treatment of masked hypertension leads
to a reduction of cardiovascular complications and is cost-
effective compared to the current standard of care, which
does not include HBP measurements and does not treat
people with normal or high-normal CBP. Until then, these
findings provide support for including HBP monitoring in
primary prevention strategies for cardiovascular disease
among individuals at risk for masked hypertension (for
example, people with diabetes), and for carrying out HBP
monitoring in people with a normal CBP but unexplained
signs of hypertensive target organ damage.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001591.
N This study is further discussed in a PLOS Medicine
Perspective by Mark Caulfield
N The US National Heart, Lung, and Blood Institute has
patient information about high blood pressure (in English
and Spanish) and a guide to lowering high blood pressure
that includes personal stories
N The American Heart Association provides information on
high blood pressure and on cardiovascular diseases (in
several languages); it also provides personal stories about
dealing with high blood pressure
N The UK National Health Service Choices website provides
detailed information for patients about hypertension
(including a personal story) and about cardiovascular
disease
N The World Health Organization provides information on
cardiovascular disease and controlling blood pressure; its
‘‘A Global Brief on Hypertension’’ was published on World
Health Day 2013
N The UK charity Blood Pressure UK provides information
about white-coat hypertension and about home blood
pressure monitoring
N MedlinePlus provides links to further information about
high blood pressure, heart disease, and stroke (in English
and Spanish)
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Perspective
Home Blood Pressure Monitoring: New Evidence for an
Expanded Role
Mark Caulfield*
Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
Cardiovascular disease is now the lead-
ing cause of death and disability worldwide
[1]. The application of electronic blood
pressure measurement (home or ambulato-
ry monitoring) has been shown to improve
the precision of diagnosis of hypertension
and is superior to conventional, or clinic,
blood pressure monitoring at predicting
prognosis in those with high blood pressure.
The global burden of hypertension now
affects over 1 billion people and contributes
to 80% of cardiovascular disease outcomes
in emergent economies [1]. From observa-
tional studies of blood pressure (mostly
clinic blood pressure) in 1 million people,
for every 20-mm Hg increment in systolic
blood pressure greater than 115 mm Hg,
there is an effective doubling of cardiovas-
cular mortality [2].
The Prognostic Role of
Electronic Blood Pressure
There are limited data on the use of
home blood pressure monitoring (HBPM)
to assess the cardiovascular risk of patients.
An analysis as part of the 2011 UK
National Institute for Health and Care
Excellence guideline for hypertension sug-
gested that ambulatory blood pressure
monitoring (ABPM) was superior to
HBPM and that both were superior to
clinic blood pressure monitoring (CBPM)
as a guide to adverse outcomes [3,4]. This
analysis led to the recommendation that
ABPM be used to confirm a diagnosis
when hypertension is suspected, but the
panel (in which I was a participant)
acknowledged that the relative lack of
data on HBPM might have affected
prognostic accuracy [3,4].
As published in this week’s PLOS
Medicine, Jan Staessen and colleagues
undertook an individual-patient meta-
analysis based on data from the Interna-
tional Database of Home Blood Pressure
in Relation to Cardiovascular Outcome.
The meta-analysis included 5,008 people
who had home and conventional blood
pressure measurements and were not being
treated with antihypertensive medications
that would have influenced prognostic
outcomes [5]. These measurements were
used to stratify participants into five
categories of blood pressure: optimal,
,120/,80 mm Hg; normal, 120–129/
80–84 mm Hg; high-normal, 130–139/
85–89 mm Hg; mild hypertension, 140–
159/90–99 mm Hg; and severe hyperten-
sion, $160/$100 mm Hg.
Home Blood Pressure
Monitoring Improves Risk
Stratification
In keeping with a previous analysis,
the meta-analysis found no significant
improvement in risk stratification in those
defined as severely hypertensive ($160/
$100 mm Hg); at these levels HBPM and
CBPM are both strong predictors of
outcomes. This is not unexpected; severe
hypertension does not lack precision in risk
stratification and is not difficult to decide
to treat. On the other hand, at every level
of blood pressure below severe hyperten-
sion, the additional measurements ob-
tained from HBPM improved risk stratifi-
cation, providing new evidence supporting
the use of HBPM in routine assessment of
risk. This result is important because it
could refine risk stratification in people
with optimal, normal, or high-normal
blood pressure based on CBPM, who are
not conventionally treated. In addition,
HBPM showed improved stratification of
risk in those with masked hypertension,
that is, those who have normal clinic blood
pressure but on HBPM or ABPM have
periods of elevated blood pressure and
may benefit from treatment [5].
These findings add depth to the evi-
dence base in favour of electronic blood
pressure monitoring in the form of HBPM.
However, the authors do not have data to
provide a head-to-head comparison of
HBPM and ABPM, which would be
valuable in assessing whether HBPM
could be of sufficient diagnostic and
Linked Research Article
This Perspective discusses the
following new study published in
PLOS Medicine:
Asayama K, Thijs L, Brguljan-Hitij J,
Niiranen TJ, Hozawa A, et al. (2014)
Risk Stratification by Self-Measured
Home Blood Pressure across Catego-
ries of Conventional Blood Pressure:
A Participant-Level Meta-Analysis
PLoS Med 11(1): e1001591. doi:10.
1371/journal.pmed.1001591
Jan Staessen and colleagues com-
pare the risk of cardiovascular,
cardiac, or cerebrovascular events
in patients with normal office blood
pressure but elevated home blood
pressure.
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prognostic precision to replace ABPM in
the confirmation of a diagnosis informing
a decision to treat. In addition, they were
not able to standardise HBPM approach-
es, but that limitation would be more likely
to dilute the observed improved risk
stratification by HBPM than create a
spurious association. To address this issue
and validate these findings, the authors
suggest further comparative, prospective
randomised controlled trials would be
valuable [5].
The Potential Implications of
These Findings for Patients with
High Blood Pressure
As the authors suggest, the use of
electronic blood pressure monitoring
(HBPM and ABPM) is likely cost-effective,
allows more rapid diagnosis and treat-
ment, saves consultation time, and may in
some people avert treatment at least
temporarily [6]. In this study by Staessen
and colleagues, HBPM appears valuable
in assessing those at risk who would not
usually be considered as potentially bene-
fiting from treatment. With a growing
burden of high blood pressure and a
growing availability of affordable devices,
HBPM could be used to diagnose high
blood pressure and help decide whom to
treat. It empowers patients to take on a
role in assessment of their blood pressure.
Now, with smart phone applications that
accept automated data uploads from
HBPM and display blood pressure trends
over time, HBPM could help avoid travel
and may save time for the health care
team as they conduct remote consultations
exploiting electronic tools for communica-
tion.
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